Comparative Pharmacology
Head-to-head clinical analysis: AVC versus SULF 10.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AVC versus SULF 10.
AVC vs SULF-10
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
AVC (sulfanilamide) is a sulfonamide antibiotic that inhibits bacterial dihydrofolate synthesis by competing with para-aminobenzoic acid (PABA), thereby blocking folic acid production and bacterial growth.
Sulfacetamide inhibits bacterial dihydropteroate synthase, blocking folate synthesis and thereby nucleic acid production.
1 applicatorful (approximately 5 g of 0.1% cream) intravaginally once daily at bedtime for 7 days.
One to two drops of SULF-10 ophthalmic solution (10% sulfacetamide sodium) instilled into the affected eye(s) every 2-3 hours initially, then decreasing frequency as infection resolves, up to 5-6 times daily.
None Documented
None Documented
3-5 hours; prolonged in renal impairment (up to 12 hours).
Terminal elimination half-life is 7-12 hours in adults with normal renal function; prolonged in renal impairment
Renal: 30-50% unchanged; biliary/fecal: 10-20% as metabolites.
Renal excretion of unchanged drug and acetylated metabolites: ~85-90%; biliary/fecal: ~10-15%
Category C
Category C
Antibiotic (Sulfonamide)
Antibiotic (Sulfonamide)